BioMarin Finalizes Acquisition of Alesta Therapeutics to Enhance Rare Disease Portfolio

BioMarin Completes Acquisition of Alesta Therapeutics

BioMarin Pharmaceutical Inc. has announced the successful completion of its acquisition of Alesta Therapeutics on September 1, 2026. This strategic move is expected to enhance BioMarin's portfolio in the domain of skeletal conditions, particularly through the addition of ALE1, a promising oral small molecule therapy aimed at treating hypophosphatasia (HPP). HPP is a rare genetic bone disorder linked to mutations in the ALPL gene, highlighting the significance of this acquisition in addressing unmet medical needs within the industry.

The acquisition was initially proposed on August 18, 2026, when BioMarin entered a definitive agreement to acquire Alesta Therapeutics. Notably, in preparation for the acquisition, Alesta transferred all non-ALE1 assets to a separate entity, allowing BioMarin to focus solely on ALE1, which is currently undergoing a Phase 1/2a clinical trial. This trial assesses the safety, tolerability, and pharmacokinetics of ALE1 in healthy volunteers and adults diagnosed with HPP.

BioMarin, based in San Rafael, California, has firmly established itself as a leader in the rare disease biotechnology space since its inception in 1997. The company aims to provide innovative medicines for patients with genetically defined conditions, boasting a successful track record that includes nine commercial therapies and a robust pipeline of clinical and preclinical candidates. By prioritizing a unique approach to drug discovery and development, BioMarin is poised to leverage genetic science to create impactful medical treatments.

About BioMarin
BioMarin Pharmaceutical is dedicated to serving individuals with genetic disorders by delivering effective therapies. With a strong commitment to innovation and excellence, BioMarin's portfolio is continuously expanding as the company seeks to redefine treatment paradigms in the realm of rare diseases.

About Alesta Therapeutics
Alesta Therapeutics specializes in developing innovative oral small-molecule therapies aimed at treating underserved diseases. The company’s flagship treatment, ALE1, is specifically designed to address hypophosphatasia, a condition that currently has limited treatment options available. By joining forces with BioMarin, Alesta’s potential will be amplified, enabling the development of solutions for patients in dire need.

Future Implications
The acquisition of Alesta Therapeutics is a significant milestone in BioMarin’s mission to expand its therapeutic capabilities. Promising prospects for ALE1 suggest that it may become the first oral treatment for hypophosphatasia, marking a crucial advancement in the management of this rare genetic disorder.

However, potential risks accompany the transaction, as highlighted by the forward-looking statements in BioMarin's announcements. The integration of Alesta into BioMarin's existing corporate structure presents challenges such as ensuring successful development and commercialization of ALE1, meeting regulatory requirements, and navigating the unpredictable path of clinical trials.

As BioMarin continues to pursue excellence in rare disease therapies, the collaboration with Alesta lays a foundation for innovation, aimed at transforming the lives of patients with genetically derived medical conditions. For further details on BioMarin and its offerings, you may visit their official site at www.biomarin.com. Those interested in Alesta can find additional information at www.alestatherapeutics.com.